Kailera Therapeutics (NASDAQ:KLRA) Trading 7.9% Higher – Here’s Why

Kailera Therapeutics, Inc. (NASDAQ:KLRA) traded up 7.9% during mid-day trading on Tuesday . The stock traded as high as $16.69 and last traded at $16.62. Approximately 185,957 shares traded hands during trading, a decline of 74% from the average session volume of 720,033 shares. The stock had previously closed at $15.40.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. William Blair assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating on the stock. Evercore initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating on the stock. TD Cowen started coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $57.00 target price on the stock. Wall Street Zen lowered Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Finally, Leerink Partners initiated coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Kailera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Kailera Therapeutics Trading Down 3.4%

The firm has a market cap of $2.05 billion and a price-to-earnings ratio of -0.00. The stock has a 50 day simple moving average of $18.73.

Kailera Therapeutics (NASDAQ:KLRA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, analysts forecast that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System purchased a new stake in Kailera Therapeutics during the 2nd quarter valued at approximately $309,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Kailera Therapeutics in the second quarter worth $24,233,000. Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics during the second quarter worth $64,308,000. Finally, Atlas Venture Life Science Advisors LLC purchased a new position in Kailera Therapeutics during the second quarter valued at $113,923,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.